Wardwell

Williams Closes Acquisition of MountainWest Natural Gas Transmission and Storage Business

Retrieved on: 
Tuesday, February 14, 2023
Other Natural Resources, Other Energy, Utilities, Oil, Gas, Energy, Natural Resources, Natural gas, TD Securities, TD, NYSE, Acquisition, Morrison & Foerster, MountainWest Sports Network, Lazard, Wardwell, FERC, J. P. Morgan, WMB

MountainWest comprises roughly 2,000-miles of interstate natural gas pipeline systems primarily located across Utah, Wyoming and Colorado, totaling approximately 8 Bcf/d of transmission capacity.

Key Points: 
  • MountainWest comprises roughly 2,000-miles of interstate natural gas pipeline systems primarily located across Utah, Wyoming and Colorado, totaling approximately 8 Bcf/d of transmission capacity.
  • MountainWest also operates 56 Bcf of total storage capacity, including the Clay Basin underground storage reservoir, providing valuable service to western markets.
  • “With the acquisition now complete, we look forward to welcoming MountainWest employees to Williams and bringing value to our shareholders by delivering safe and reliable services to both Williams and MountainWest customers as we increase the utilization of our existing large scale platforms.”
    With the acquisition of MountainWest, Williams expands its infrastructure network and increases its business mix of FERC-regulated natural gas transmission and storage.
  • The acquisition expands Williams’ services to key Rockies markets, including natural gas delivery into Salt Lake City and other demand markets not previously served by Williams.

Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination With Compute Health Acquisition Corp.

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Technology, Professional Services, Health, General Health, Other Technology, Medical Devices, Surgery, Nanotechnology, Fitness & Nutrition, Finance, Slate, LLP, NYSE, Safety, Acquisition, Chef, Kirkland & Ellis, RTW, Political moderate, Overweight, Credit Suisse, Weight loss, PIPE, Sleep, Fortification, ESTA, Jefferies Group, Type 2 diabetes, LP, Entrepreneurship, Anesthesia, Prediabetes, Growth, IP, Mental health, MD, DNA, Life, Security (finance), Obesity, Patient, Fortress Investment Group, Harvard Medical School, Endoscopy, Fear, Diet, Intellectual property, Skadden, Arps, Slate, Meagher & Flom, Artificial intelligence, Form, Wardwell, A1C, Investment, Cryptocurrency, Medical device, Pharmaceutical industry, Financial services, Jefferies

While weight loss drugs have shown to be effective, they often need to be used for life at significant costs and can result in undesirable side effects.

Key Points: 
  • While weight loss drugs have shown to be effective, they often need to be used for life at significant costs and can result in undesirable side effects.
  • Both patients and providers are in need of clinically proven weight loss solutions that can scale globally and address these shortcomings.
  • “The global opportunity to reliably drive safe and effective weight loss taps both medical and aesthetic needs of consumers and has unlimited potential.
  • In connection with the proposed transaction, holders of Compute Health Class A common stock will have the right to redeem their Compute Health Class A shares.

Bowlero Corp. Announces Refinancing of Term Loan B and Upsizing of Revolver in Leverage-Neutral Transaction, Bolsters Liquidity

Retrieved on: 
Wednesday, February 8, 2023
Professional Services, Entertainment, Business, Sports, General Entertainment, Finance, Bowling, SOFR, Security (finance), NYSE, Form, Wardwell, Credit Suisse, Bank

Bowlero Corp. (NYSE: BOWL) (“Bowlero” or the “Company”), the world’s largest owner and operator of bowling centers, announced today that the Company successfully closed $900 million term loan B due February 8, 2028 in a net-leverage-neutral transaction.

Key Points: 
  • Bowlero Corp. (NYSE: BOWL) (“Bowlero” or the “Company”), the world’s largest owner and operator of bowling centers, announced today that the Company successfully closed $900 million term loan B due February 8, 2028 in a net-leverage-neutral transaction.
  • At the same time, Bowlero upsized its existing revolving credit facility by $35 million, increasing drawdown capacity to $200 million and bolstering the Company’s go-forward liquidity.
  • The primary uses of proceeds from the transaction are to refinance the existing term loan B, repay outstanding existing borrowings under the revolving credit facility, and for general corporate purposes.
  • Please refer to the Form 8-K filed with the Securities and Exchange Commission for additional information on the terms of the amended credit agreement.

Veritas Capital Completes Acquisition of Wood Mackenzie

Retrieved on: 
Thursday, February 2, 2023
Professional Services, Agriculture, Utilities, Natural Resources, Oil, Gas, Data Analytics, Alternative Energy, Environment, Energy, Finance, Sustainability, Government, VRSK, Veritas Capital, Gibson Dunn, Capital, Software, Partnership, Morgan Stanley, Growth, Wardwell, Wood Mackenzie, Renewable energy, Veritas, Verisk Analytics

Veritas Capital (“Veritas”), a leading investor at the intersection of technology and government, today announced that an affiliate of Veritas has completed the purchase of Wood Mackenzie from Verisk (Nasdaq: VRSK).

Key Points: 
  • Veritas Capital (“Veritas”), a leading investor at the intersection of technology and government, today announced that an affiliate of Veritas has completed the purchase of Wood Mackenzie from Verisk (Nasdaq: VRSK).
  • The Wood Mackenzie Lens© platform enables world class analytics and insights to drive critical decision making for the company’s longstanding clients that operate at the leading edge of the rapidly evolving energy sector.
  • Mark Brinin, Chief Executive Officer for Wood Mackenzie said, “We are excited to embark on the next chapter for Wood Mackenzie in partnership with Veritas.
  • “We are excited to welcome Wood Mackenzie to the Veritas portfolio and partner with the team to drive its next phase of growth,” said Ramzi Musallam, Chief Executive Officer and Managing Partner of Veritas.

Verisk Announces Closing of Wood Mackenzie Sale

Retrieved on: 
Thursday, February 2, 2023
Wood Mackenzie, Veritas Capital, Government, Wardwell, Sale, Gibson, Dunn & Crutcher, Environmental health, Growth, VRSK, Financial adviser, Verisk Analytics, Veritas

JERSEY CITY, N.J., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading global data analytics provider, today announced the closing of the sale of Wood Mackenzie to an affiliate of Veritas Capital (“Veritas”), a leading investor at the intersection of technology and government.

Key Points: 
  • JERSEY CITY, N.J., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading global data analytics provider, today announced the closing of the sale of Wood Mackenzie to an affiliate of Veritas Capital (“Veritas”), a leading investor at the intersection of technology and government.
  • “This marks a significant value-creating step for Verisk, which returns the company to its roots as a dedicated strategic partner to the global insurance industry,” said Lee Shavel, president and CEO, Verisk.
  • The terms of the sale of Wood Mackenzie to Veritas were described in a previous press release, which can be found here .
  • Morgan Stanley & Co LLC is acting as financial advisor and Davis Polk & Wardwell LLP as legal advisor to Verisk in connection with the transaction.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Janus, Disease, Autoimmune disease, CNCE, CVR, Woman, Concert Communications Services, Dermatology, Sale, Acquisition, NSE, R, JAK1, Depression, Hair loss, Immune system, Food, JAK2, Life, CVR Partners, Wardwell, Sun Pharma, BSE, Common stock, Deuterium, FDA, Scalp, Reuters, Investment, Hair, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Treatment, NDA, Patient, Alopecia areata, Janus kinase, Concert, Pharmaceutical industry, Security (finance), Ophthalmology

Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].

Key Points: 
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime[1],[2],[3].
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert's commitment to supporting the Alopecia Areata patient community.
  • Under the terms of the merger agreement, Sun Pharma will promptly commence a tender offer to acquire all outstanding shares of Concert common stock.

EMERSON ANNOUNCES PREMIUM, ALL-CASH PROPOSAL TO ACQUIRE NATIONAL INSTRUMENTS FOR $53 PER SHARE

Retrieved on: 
Tuesday, January 17, 2023
National Instruments, EPS, Sidley Austin, Hand, Test, Centerview Partners, Automation, NYSE, Eastern Time Zone, NI, NATI, Conference, History, EMR, Growth, Engineering, TAM, LabVIEW, Rosemount, APM Automation Solutions, Software, Hearing, Public Announcement, Letter, Conference call, Management system, Wardwell, Acquisition, Central Time, Health insurance, Security (finance), Mobile phone, Bank, Network equipment, Medical device, Airline, Renewable energy, Pharmaceutical industry

Emerson has made numerous attempts to engage constructively with NI in private since May 16, 2022, as outlined in the correspondence below.

Key Points: 
  • Emerson has made numerous attempts to engage constructively with NI in private since May 16, 2022, as outlined in the correspondence below.
  • In a letter dated January 11, 2023, Emerson reiterated its $53 per share proposal to acquire NI.
  • Further to my recent discussions with you, I am excited to present you with this proposal (the "Proposal") for the acquisition of all outstanding shares of National Instruments Corporation ("NI") by Emerson Electric Co. ("Emerson").
  • On behalf of Emerson, I thank you again for the dialogue thus far and for your consideration of this Proposal.

Cepton, Inc. Announces Closing of $100 Million Investment from Koito Manufacturing

Retrieved on: 
Friday, January 20, 2023
Automotive Manufacturing, Consumer Electronics, Automotive, Technology, Manufacturing, Semiconductor, Other Technology, General Automotive, Autonomous Driving, Vehicles, Vehicle Technology, Engineering, Investment, Security (finance), Securities and Exchange Commission (Nigeria), Myers, Partnership, OEM, TSE, Growth, Nishimura & Asahi, Tier 1, Multimedia, Nishimura, Wardwell, Renewable energy

Cepton, Inc. (“Cepton”) (Nasdaq: CPTN), a Silicon Valley innovator and leader in high performance lidar solutions , announced today the completion of its previously announced $100 million investment (the “Investment”) from its long-term automotive Tier 1 partner and current shareholder, Koito Manufacturing Co., Ltd. (“Koito”) (TSE: 7276) on January 19, 2023.

Key Points: 
  • Cepton, Inc. (“Cepton”) (Nasdaq: CPTN), a Silicon Valley innovator and leader in high performance lidar solutions , announced today the completion of its previously announced $100 million investment (the “Investment”) from its long-term automotive Tier 1 partner and current shareholder, Koito Manufacturing Co., Ltd. (“Koito”) (TSE: 7276) on January 19, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230120005052/en/
    “We’re happy to announce the closing of the preferred stock investment as we deepen our partnership with Koito,” said Dr. Jun Pei, Cepton’s Co-Founder and CEO.
  • “This is an important year for us as we work towards commercialization and scale manufacturing of our lidar products.
  • SMBC Nikko served as exclusive financial advisor to Koito and Davis Polk & Wardwell LLP and Nishimura & Asahi served as legal counsel to Koito.

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Retrieved on: 
Thursday, January 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Janus, Disease, Sun Pharma, BSE, NSE, Autoimmune disease, R, CNCE, JAK1, CVR, Depression, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Safety, Deuterium, FDA, Hair loss, NDA, Woman, Immune system, Scalp, Food, Patient, CVR Partners, JAK2, Sale, Acquisition, Multimedia, Janus kinase, Reuters, Alopecia areata, Life, Investment, Concert, Hair, Wardwell, Security (finance), Pharmaceutical industry, Ophthalmology

Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.

Key Points: 
  • Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
  • Alopecia Areata may affect up to 2.5% of the United States and global population during their lifetime1,2,3.
  • The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib,” said Abhay Gandhi, CEO North America, Sun Pharma.
  • “There is a significant unmet need in the Alopecia Areata space and we aim to build on Concert’s commitment to supporting the Alopecia Areata patient community.